No Data
No Data
Reduce the risk of brain metastasis, Johnson & Johnson's blockbuster therapy is approved again.
The press release pointed out that, compared to chemotherapy alone, amivantamab in combination with chemotherapy is the first treatment to show a significant improvement in progression-free survival (PFS) in this patient population.
Addex Stock Rallies 45% on Indivior Collaboration Update
Johnson & Johnson's Janssen-Cilag Gets European Commission's Expanded Approval for Rybrevant
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Express News | J&J: EU Approves Rybrevant (Amivantamab) in Combination With Chemotherapy
No Data